Recent developments include the announcement of a $1.5 billion business combination agreement with Nanyang Biologics Pte. Ltd. to pursue a public listing, plans by The9's Singapore investee NYB to go Nasdaq via this business combination, and an updated per share redemption price announced in connection with an upcoming special meeting.

• RF Acquisition Corp II entered into a business combination agreement with Nanyang Biologics Pte. Ltd., an AI drug discovery pioneer, in a $1.5 billion transaction to pursue a public listing [N1].
• The9's Singapore investee NYB announced plans to go Nasdaq via the $1.5 billion business combination with RF Acquisition Corp II [N2].
• The company announced an updated per share redemption price in connection with an upcoming special meeting [N3].

The company’s focus on deep technology sectors such as artificial intelligence, quantum computing, and biotechnology in Asia aligns with high-growth and innovative industries. The management team’s experience and broad network may facilitate sourcing and executing a valuable business combination. The recent announced $1.5 billion business combination agreement with Nanyang Biologics Pte. Ltd., an AI drug discovery pioneer, represents a significant milestone toward achieving the company’s strategic objectives [N1][N2].

The company currently has no operating revenues and limited liquidity, with a current ratio of 0.06 as of June 30, 2026, indicating potential financial constraints before completing a business combination. The success of the company depends entirely on completing a suitable business combination within the prescribed timeframe; failure to do so would result in liquidation and loss of investment value. The personal and financial interests of executives and directors may influence the timing and terms of the business combination, which could pose conflicts of interest [S1].

As a blank check company, RF Acquisition Corp II does not have an operating business or products and thus does not possess a traditional economic moat. Its potential competitive advantage lies in the experience and network of its management team and sponsor, which may provide access to attractive acquisition targets in the deep technology sector in Asia. The company’s ability to leverage these relationships and execute a successful business combination could create value, but this is contingent on future events and execution.

• Business Combination Deadline Risk: The company must complete a business combination within 27 months of the IPO closing or redeem public shares from the trust account, with private placement units and rights expiring worthless if not completed [S1].
• Liquidity Risk: As of June 30, 2026, the company has very limited liquidity with a current ratio of 0.06 and no cash and cash equivalents, which may constrain operations prior to a business combination [S2].
• Conflict of Interest Risk: The personal and financial interests of executive officers and directors may influence their motivation in completing a business combination and subsequent operations, especially as the deadline approaches [S1].
• No Operating Revenues: The company has not commenced operations and generates income only from interest on IPO proceeds until a business combination is completed [S1].

• RF Acquisition Corp II is a Cayman Islands exempted blank check company incorporated on February 5, 2024, formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination (Business Combination) [S1].
• The company focuses its search for a Business Combination on target businesses in Asia within the deep technology sector, including artificial intelligence, quantum computing, and biotechnology, excluding entities with China operations consolidated through a VIE structure [S1].
• As of December 31, 2025, the company had not commenced operations and generates non-operating income from interest on proceeds from its Initial Public Offering (IPO) [S1].
• The IPO was completed on May 21, 2024, with 10 million units sold at $10 each, plus a 1.5 million unit over-allotment option exercised, raising gross proceeds of $115.575 million placed in a trust account invested in U.S. government securities [S1].
• The company sold private placement units to its Sponsor and EarlyBirdCapital, Inc., generating additional proceeds of $4 million [S1].
• The company’s management team has experience in managing and operating companies, executing M&A strategies, sourcing and structuring deals, and accessing capital markets in Asia and America [S1].
• The company’s acquisition criteria include strong management teams, revenue and earnings growth potential, strong free cash flow generation, market leadership, and appropriate valuations [S1].
• The company must complete a Business Combination within 27 months of the IPO closing or redeem public shares from the trust account, with private placement units and rights expiring worthless [S1].
• As of June 30, 2026, the company reported cash and cash equivalents of $0, current assets of $77,938, current liabilities of $1,361,041, resulting in a current ratio of 0.06 and a cash ratio of 0, indicating very limited liquidity [S2].
• The company reported net income of $104,427 for the quarter ended June 30, 2026 [S2].
• Recent news includes a business combination agreement with Nanyang Biologics Pte. Ltd., an AI drug discovery company, in a $1.5 billion transaction to pursue a public listing [N1].
• The9's Singapore investee NYB announced plans to go Nasdaq via the $1.5 billion business combination with RF Acquisition Corp II [N2].
• The company announced an updated per share redemption price in connection with an upcoming special meeting [N3].